|Source||Humanized (from mouse)|
|(what is this?)|
Cantuzumab mertansine (SB-408075; huC242-DM1) is an antibody-drug conjugate investigated to treat colorectal cancer and other types of cancer. It is a humanized monoclonal antibody, cantuzumab (huC242) linked to a cytotoxic agent, mertansine (DM1). It was developed by ImmunoGen.
After the huC242 mab binds to the external domain of CanAg, the cantuzumab mertansine-CanAg complex is internalized, and the DM1 molecules are released intracellularly by cleavage of the DM1-huC242 disulfide bonds.
- Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association. Archived 2011-06-04 at the Wayback Machine
- Rodon, J; Garrison, M; Hammond, LA; de Bono, J; Smith, L; Forero, L; Hao, D; Takimoto, C; Lambert, JM; Pandite, L; Howard, M; Xie, H; Tolcher, AW (2008). "Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study". Cancer Chemother Pharmacol. 62: 911–9. doi:10.1007/s00280-007-0672-8. PMID 18301896.
- A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004
|This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|